Concepedia

Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer

Jianhua Chang, Yi‐Long Wu, Shun Lü, Jie Wang, Tony Mok, Li Zhang, Jifeng Feng, Lin Wu, Hai‐Yan Tu, Yiping Zhang,

Lung Cancer · 2021 · 18 citations · 23 references

DOI

Concepts

References

23

Cancer statistics, 2020

Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2020 · 21K citations · Full text

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

H. Borghaei, L. Paz-Ares, Leora Horn et al. · New England Journal of Medicine · 2015 · 9.3K citations · Full text

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Julie R. Brahmer, Karen L. Reckamp, Paul Baas et al. · New England Journal of Medicine · 2015 · 8.4K citations · Full text

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Achim Rittmeyer, Fabrice Barlési, Daniel Waterkamp et al. · The Lancet · 2016 · 4.7K citations · Full text

, , +12

Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer

A. Simon Pickard, Maureen P. Neary, David Cella · Health and Quality of Life Outcomes · 2007 · 886 citations · Full text